Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Boston, Massachusetts 02114


This is a randomized, double blind, placebo controlled, multicenter, phase II study to compare the anti-tumor activity as measured by progression-free survival (PFS) and the tolerability of sorafenib in combination with dacarbazine (DTIC) versus DTIC in combination with placebo in subjects with unresectable Stage III or Stage IV melanoma who have not received prior cytotoxic chemotherapy. A total of approximately 98 subjects will be randomized to receive DTIC + sorafenib or DTIC + placebo.


Inclusion Criteria: - Patients who have a life expectancy of at least 12 weeks - Patients with histologically or cytologically confirmed unresectable (Stage III) or metastatic (Stage IV) melanoma - Patients who have an ECOG PS of 0, or 1 - Measurable disease defined as at least one lesion that can be accurately and serially measured per the modified RECIST criteria Exclusion Criteria: - Primary ocular or mucosal melanoma - Previous or concurrent cancer that is distinct in primary site or histology from the cancer being evaluated in this study except cervical carcinoma in situ, treated basal cell carcinoma, superficial bladder tumors (TA, Tis & Ti) or any cancer curatively treated < 3 years prior to study entry - History of cardiac disease - Known history of human immunodeficiency virus (HIV) infection



Primary Contact:

Study Director
Bayer Study Director

Backup Contact:


Location Contact:

Boston, Massachusetts 02114
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: January 21, 2020

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.